Blog

Viktor Grunwald: Real-world cabozantinib after ICI

Photo from Viktor Grunwald/X

Sep 14, 2024, 13:51

Viktor Grunwald: Real-world cabozantinib after ICI

Viktor Grunwald, Professor of Interdisciplinary Genitourinary (GU) Oncology at the University Hospital Essen, shared a post on X, about paper published in Clinical Genitourinary Cancer:

Final Analysis of a Noninterventional Study on Cabozantinib in Patients With Advanced Renal Cell Carcinoma After Prior Checkpoint Inhibitor Therapy of the German Interdisciplinary Working Group on Renal Tumors (IAG-N).

Authors: Grünwald Viktor, Bögemann Martin, Rafiyan Mohammad-Reza, Niegisch Günter, Schnabel Marco, Flörcken Anne, Maasberg Michael, Maintz Christoph, Zahn Mark-Oliver, Wortmann Anke, Hinkel Andreas, Casper Jochen, Darr C, Hilser Thomas, Schulze M, Sookthai Disorn, Ivanyi Philipp.

”Real-world cabozantinib after ICI:

Similar efficacy (shorter OS) compared to METEOR.
62% had lower starting doses (<60mg).
Similar outcome in low vs. 60 mg starting dose.
Less toxicity with lower dose.
Let’s re-think cabozantinib dosing.”

Source: Viktor Grunwald/X

Bögemann Martin Cabozantinib cancer Casper Jochen Clinical Genitourinary Cancer Darr C Flörcken Anne Grünwald Viktor Hilser Thomas Hinkel Andreas Ivanyi Philipp Maasberg Michael Maintz Christoph Niegisch Günter OncoDaily Oncology Rafiyan Mohammad-Reza Schnabel Marco Schulze M Sookthai Disorn University Hospital Essen Viktor Grünwald Wortmann Anke Zahn Mark-Oliver

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage